Transgenic animals with altered high-density lipoprotein composition and functions

Current Opinion in Lipidology

Volumn 11, Issue 2, 2000, Pages 149-153

  Kalopissis, Athina Despina ^a   Chambaz, Jean ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; CARRIER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE;

ATHEROSCLEROSIS; HUMAN; LIPID COMPOSITION; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEIN METABOLISM; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; REVIEW; TRANSGENIC ANIMAL;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; HUMANS; KINETICS; LIPASE; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; LIVER; MICE; MICE, TRANSGENIC;

ANIMALIA;

EID: 0034089183     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200004000-00007     Document Type: Review

References (54)

1. 1 Miller GJ, Miller NE. Plasma HDL concentration and development of ischaemic heart disease. Lancet 1975; 1:16-19.
2. 2 Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. JAMA 1986; 256:2835-2838.
3. 3 Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36:211-228.
4. 4 Banka CL. HDL and lipoprotein oxidation. Curr Opin Lipidol 1996; 7:139-142.
5. 5 Brooks-Wilson A, Marcil M, Clee SM, Zhang L-H, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial HDL deficiency. Nat Gene 1999; 22:336-345. The identification of the molecular defect in Tangier disease is a major breakthrough for the elucidation of HDL formation.
6. 6 Bodzioch M, Orso E, Klucken J, Langmann T, Böttcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347-351. The identification of the molecular defect in Tangier disease is a major breakthrough for the elucidation of HDL formation.
7. 7 Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette J-C, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22:352-355. The identification of the molecular defect in Tangier disease is a major breakthrough for the elucidation of HDL formation.
8. 8 Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR. Targeted mutation of plasma PLTP gene markedly reduces HDL levels. J Clin Invest 1999; 103:907-914. This is an excellent study establishing the essential role of PLTP in the transfer of VLDL surface lipids to HDL.
9. 9 Weinstock PH, Bisgaier CL, Aalto-Setälä K, Radner H, Ramakrishnan R, Levak-Frank S, et al. Severe hypertriglyceridemia, reduced HDL, and neonatal death in lipoprotein lipase knockout mice. J Clin Invest 1995; 96:2555-2568.
10. 10 Levak-Frank S, Hofmann W, Weinstock PH, Radner H, Sattler W, Breslow JL, Zechner R. Induced mutant mouse lines that express lipoprotein lipase in cardiac muscle, but not in skeletal muscle and adipose tissue, have normal plasma triglyceride and HDL-cholesterol levels. Proc Natl Acad Sci USA 1999; 96:3165-3170. In this study the expression of LPL in cardiac muscle only was sufficient to normalize VLDL catabolism.
11. 11 Shimada M, Shimano H, Gotoda K, Yamamoto K, Kawamura M, Inaba T, et al. Overexpression of human lipoprotein lipase in transgenic mice. Resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. J Biol Chem 1993; 268:17924-17929.
12. 12 Rye K-A, Clay MA, Barter PJ. Remodelling of HDL by plasma factors. Atherosclerosis 1999; 145:227-238.
13. 13 Jiang X, Francone OL, Bruce C, Millne R, Mar J, Walsh A, et al. Increased preβ-HDL, apolipoprotein A-I and phospholipid in mice expressing the human PLTP and human apo A-I transgenes. J Clin Invest 1996; 98:2373-2380.
14. 14 Föger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer Jr HB. Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma HDL and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem 1997; 272:27393-27400.
15. 15 Ehnholm S, Willems van Dijk K, van't Hoft B, van der Zee A, Olkkonen VM, Jauhiainen M, et al. Adenovirus mediated overexpression of human PLTP alters plasma HDL levels in mice. J Lipid Res 1998; 39:1248-1253.
16. 16 Berard AM, Remaley AT, Vaisman BL, Paigen B, Hoyt RF, Meyn SM, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing LCAT. Nat Med 1997; 3:744-749.
17. 17 Dugi KA, Vaisman BL, Sakai N, Knapper CL, Meyn SM, Brewer Jr HB, Santamarina-Fojo S. Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice. J Lipid Res 1997; 38:1822-1832.
18. 18 Rigotti A, Trigatti B, Babitt J, Penman M, Xu S, Krieger M. Scavenger receptor BI - a cell surface receptor for HDL. Curr Opin Lipidol 1997; 8:181-188.
19. 19 Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D, Breslow JL, Tall AR. Hepatic scavenger receptor BI promotes rapid clearance of HDL free cholesterol and its transport into bile. J Biol Chem 1999; 274:33398-33402.
20. 20 Collet X, Tall AR, Serajuddin H, Guendouzi K, Royer L, Oliveira H, et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL by cells expressing scavenger receptor BI. J Lipid Res 1999; 40:1185-1193. The remodelling of HDL by the synergistic actions of CETP and hepatic lipase enhances selective HDL-cholesteryl ester uptake by SR-BI.
21. 21 Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in apoE and LDL receptor gene knockout mice as a result of human CETP transgene expression. Arterioscler Thromb Vasc Biol 1999; 19:1105-1110.
22. 22 Lambert G, Chase MB, Bensadoun A, Brewer Jr HB, Santamarina-Fojo S. Hepatic lipase promotes the selective uptake of HDL-cholesteryl esters via the scavenger receptor BI. J Lipid Res 1999; 40:1294-1303. A convincing demonstration that hepatic lipase promotes selective uptake of HDL-cholesteryl esters by SR-BI by both its lipolytic and its ligand role.
23. 23 Arai T, Rinninger F, Varban L, Fairchild-Huntress V, Liang C-P, Chen W, et al. Decreased selective uptake of HDL cholesteryl esters in apolipoprotein E knock-out mice. Proc Natl Acad Sci USA 1999; 96:12050-12055.
24. 24 Wang N, Arai T, Ji Y, Rinninger F, Tall AR. Liver-specific overexpression of SR-BI decreases levels of VLDL apoB, LDL apoB, and HDL in transgenic mice. J Biol Chem 1998; 273:32920-32926. The role of SR-BI in vivo is extended to the lowering of apo B-containing lipoproteins.
25. 25 Ueda Y, Ryer L, Gong E, Zhang J, Cooper PN, Francone O, Rubin EM. Lower plasma levels and accelerated clearance of HDL and non-HDL cholesterol in SR-BI transgenic mice. J Biol Chem 1999; 274:7165-7171. In this study increased hepatic expression of SR-BI accelerates the catabolism of HDL and non-HDL lipoproteins.
26. 26 Arai T, Wang N, Bezouevski M, Welsh C, Tall AR. Decreased atherosclerosis in heterozygous LDL receptor-deficient mice expressing the SR-BI transgene. J Biol Chem 1999; 274:2366-2371.
27. 27 Colvin P, Moriguchi E, Barrett H, Parks J, Rudel L. Production rate determines plasma concentration of large HDL in non-human primates. J Lipid Res 1998; 39:2076-2085.
28. 28 Walsh A, Ito Y, Breslow JL. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small HDL particles comparable to human HDL. J Biol Chem 1989; 264:6488-6494.
29. 29 Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new HDL size subclasses. Proc Natl Acad Sci USA 1991; 88:434-438.
30. 30 Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993; 365:762-764.
31. Milano. Atherosclerosis 1998; 136:139-146.
32. 32 Schultz JR, Gong EL, McCall MR, Nichols AV, Clift SM, Rubin EM. Expression of human apolipoprotein A-II and its effect on HDL in transgenic mice. J Biol Chem 1992; 267:21630-21636.
33. 33 Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, Julve-Gil J, Shen J, Calvet-Marquez S, et al. Functional LCAT deficiency and HDL deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem 1996; 271:6720-6728.
34. 34 Boisfer E, Lambert G, Atger V, Tran ON, Pastier D, Benetollo C, et al. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective VLDL hydrolysis. J Biol Chem 1999; 274:11564-11572. This is the first demonstration that high expression of human apo AII in vivo inhibits LPL and hepatic lipase activities and induces hypertriglyceridaemia.
35. 35 Hedrick CC, Castellani LW, Warden CH, Puppione DL, Lusis AJ. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem 1993; 268:20676-20682.
36. 36 Warden CH, Hedrick CC, Qiao J-H, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993; 261:469-472.
37. 37 Escolà-Gil JC, Marzal-Casacuberta A, Julve-Gil J, Ishida BY, Ordonez-Llanos J, Chan L, et al. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J Lipid Res 1998; 39:457-462.
38. 38 Weng W, Brandenburg NA, Zhong S, Halkias J, Wu L, Jiang X-C, et al. Apo A-II maintains HDL levels in part by inhibition of hepatic lipase: studies in apo A-II and hepatic lipase knockout mice. J Lipid Res 1999; 40:1064-1070. By inhibiting hepatic lipase activity, human apo AII may maintain HDL cholesterol levels.
39. 39 Jaye M, Lynch KJ, Krawiek J, Marchadier D, Maugeais C, Doan K, et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 1999; 21:424-428. The overexpression of this novel lipase drastically reduces plasma HDL levels. The endothelial synthesis of this lipase suggests a potential role in reverse cholesterol transport.
40. 40 Lagocki PA, Scanu AM. In vitro modulation of the apolipoprotein composition of HDL. Displacement of apolipoprotein A-I from HDL by apolipoprotein A-II. J Biol Chem 1980; 255:3701-3706.
41. 41 Lambert G, Decout A, Vanloo B, Rouy D, Duverger N, Kalopissis AD, et al. The C-terminal helix of human apolipoprotein A-II promotes the fusion of unilamellar liposomes and displaces apolipoprotein A-I from HDL. Eur J Biochem 1998; 253:328-338.
42. 42 Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999; 103:1191-1199. This is the first direct demonstration in humans that triglyceride enrichment of HDL enhances HDL-apo AI clearance.
43. 43 Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of HDL cholesterol. J Clin Invest 1993; 91:1743-1752.
44. 44 Glass C, Pittman RC, Civen M, Steinberg D. Uptake of HDL-associated apoprotein A-I and cholesterol esters by 16 tissues of the rat in vivo and by adrenal cells and hepatocytes in vitro. J Biol Chem 1985; 260:744-750.
45. 12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of HDL. Nat Med 1999; 5:656-661. This is an elegant study identifying cubilin as a high affinity apo AI receptor.
46. 12 complex, mediates HDL holoparticle endocytosis. Proc Natl Acad Sci USA 1999; 96:10158-10163. A role for cubilin is suggested in the embryonic acquisition of maternal HDL and renal catabolism of filterable forms of HDL.
47. 47 Spady DK, Woollett LA, Meidell RS, Hobbs HH. Kinetic characteristics and regulation of of HDL cholesteryl ester and apolipoprotein transport in the apo A-I-I- mouse. J Lipid Res 1998; 39:1483-1492.
48. 48 Silver DL, Jiang X-C, Tall AR. Increased HDL, defective hepatic catabolism of apo A-I and apo A-II, and decreased apo A-I mRNA in ob/ob mice. J Biol Chem 1999; 274:4140-4146. This interesting study holds promise for the future identification of the putative HDL holoparticle receptor in liver.
49. 49 Alaupovic P, Knight-Gibson C, Wang C-S, Downs D, Koren E, Brewer Jr HB, Gregg RE. Isolation and characterization of an apoA-II-containing lipoprotein [LP-A-II:B complex] from plasma VLDL of patients with Tangier disease and type V hyperlipoproteinemia. J Lipid Res 1991; 32:9-19.
50. 50 Li H, Reddick RL, Maeda N. Lack of apo A-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13:1814-1821.
51. 51 Weng W, Breslow JL. Dramatically decreased HDL cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci USA 1996; 93:14788-14794.
52. 52 Duverger N, Tremp G, Caillaud J-M, Emmanuel F, Castro G, Fruchart J-C, et al. Protection against atherogenesis in mice mediated by human apolipoprotein AIV. Science 1996; 273:966-968.
53. 53 Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 1995; 96:2170-2179.
54. 54 Holvoet P, Danloy S, Deridder E, Lox M, Bernar H, Dhoest A, Collen D. Substitution of the carboxyl-terminal domain of apo A-I with apo A-II sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice. J Clin Invest 1998; 102:379-385.